| Autor: |
Prakash K; Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Chandorkar A; Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN 55455, USA., Saharia KK; Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2021 May 13; Vol. 11 (5). Date of Electronic Publication: 2021 May 13. |
| DOI: |
10.3390/diagnostics11050875 |
| Abstrakt: |
Cytomegalovirus (CMV) is one of the most important opportunistic infections in solid organ transplant (SOT) recipients. However, current techniques used to predict risk for CMV infection fall short. CMV-specific cell mediated immunity (CMI) plays an important role in protecting against CMV infection. There is evidence that assays measuring CMV-CMI might better identify SOT recipients at risk of complications from CMV compared to anti-CMV IgG, which is our current standard of care. Here, we review recently published studies that utilize CMV-CMI, at various points before and after transplantation, to help predict risk and guide the management of CMV infection following organ transplantation. The evidence supports the use of these novel assays to help identify SOT recipients at increased risk and highlights the need for larger prospective trials evaluating these modalities in this high-risk population. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
